[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-or-overweight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-or-overweight":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,65,85,108,128,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642692","phase-3-efficacy-safety-and-tolerability-of-switching-from-glucagon-like-peptide-1-receptor-agonists-glp-1ra-to-maridebart-cafraglutide-in-adults-with-obesity-or-overweight-maritime-switch-100642692",false,"NCT07575399","Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)","A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight","Inclusion Criteria:\n\n* Body Mass Index (BMI) ≥ 25 at screening.\n* Weight loss of ≥ 10% on weekly GLP-1 RA.\n* Stable body weight.\n* Stable dose of GLP-1RA.\n* Stable gastrointestinal (GI) tolerability.\n* Contraception for females.\n* Willingness to follow trial procedures for the duration of the trial.\n\nExclusion Criteria:\n\n* Obesity induced by other endocrine disorders (ex: Cushing's syndrome).\n* Previous or planned surgical, endoscopic or device-based treatment for obesity.\n* History of malignancy.\n* Type 1\u002FType 2 diabetes mellitus (DM).\n* Family or personal history of medullary thyroid cancer.\n* Previous participation in a Maridebart Cafraglutide trial.","ALL","18 Years","99 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.",[27],"Obesity or Overweight","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2026-05-11",{"date":36,"type":21},"2028-02-28",{"name":38,"class":39},"Amgen","INDUSTRY",43,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100619933","phase-3-a-clinical-study-to-evaluate-the-effects-of-enicepatide-ro7795068-in-participants-with-obesity-or-overweight-and-type-2-diabetes-100619933","NCT07351058","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes","Enith2","Inclusion Criteria:\n\n* Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)\n* Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet\u002Fexercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy.\n* Body mass index (BMI) ≥27.0 kg\u002Fm\\^2\n* History of ≥1 self-reported unsuccessful diet\u002Fexercise effort to lose body weight\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosis or history of hyperosmolar state\u002Fcoma within 12 months prior to screening\n* Have had 1 or more episodes of severe hypoglycemia and\u002For has hypoglycemia unawareness within the 6 months prior to screening\n* At least 2 confirmed fasting blood glucose values \\>270 mg\u002FdL (15.0 mmol\u002FL) (on 2 non-consecutive days) during screening\n* Self-reported change in body weight \\>5 kg within 3 months prior to screening\n* Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)\n* Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.\n* Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)\n* Poorly controlled hypertension at screening\n* Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)\u002Ftransient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure\n* Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1\u002FGIP receptor dual agonist, GLP-1\u002FGIP\u002FGluc receptor triple agonist) within 6 months prior to randomization",{"count":50,"type":21},1600,[24],"The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).",[27,54],"Type 2 Diabetes Mellitus","2026-06-19",{"date":57,"type":32},"2026-06-23",{"date":59,"type":32},"2026-03-23",{"date":61,"type":21},"2028-08-07",{"name":63,"class":39},"Hoffmann-La Roche",122,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100619932","phase-3-a-clinical-study-to-evaluate-the-effects-of-enicepatide-ro7795068-in-participants-with-obesity-or-overweight-without-type-2-diabetes-100619932","NCT07351045","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes","Enith1","Inclusion Criteria:\n\n* Participants must have at screening:\n\n  1. Body mass index (BMI) greater than or equal to (≥)30.0 kg\u002Fm\\^2; or\n  2. BMI ≥27.0 kg\u002Fm\\^2 and \\\u003C30.0 kg\u002Fm\\^2 with at least one weight-related comorbidity, such as prediabetes, hypertension, dyslipidemia, diagnosis of obstructive sleep apnea, or weight-related cardiovascular disease\n* History of ≥1 self-reported unsuccessful diet\u002Fexercise effort to lose body weight\n* Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)\n\nExclusion Criteria:\n\n* History of Type 1 diabetes mellitus (T1DM) or T2DM, or history of ketoacidosis or hyperosmolar state\u002Fcoma. Prior, but not current, diagnosis of gestational diabetes is allowed if no history of diabetes is recorded since.\n* Self-reported change in body weight \\>5 kg within 3 months prior to screening\n* Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)\n* Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.\n* Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)\n* History of acute or chronic pancreatitis or clinically significant gallbladder disease. History of acute pancreatitis caused by gallstones or clinically significant gallbladder disease is allowed if the participant had a cholecystectomy to resolve the problem at least 3 months prior to screening.\n* Poorly controlled hypertension at screening\n* Any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)\u002Ftransient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure.\n* Have a history of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, or other serious mood or anxiety disorder). Participants with MDD or generalized anxiety disorder whose disease state is considered stable within 1 year prior to screening and expected to remain stable throughout the course of the study, in the opinion of the investigator, are allowed provided that they are not receiving prohibited medication.\n* Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1\u002FGIP receptor dual agonist, GLP-1\u002FGIP\u002FGluc receptor triple agonist) within 6 months prior to randomization",{"count":74,"type":21},2000,[24],"The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.",[27],{"date":57,"type":32},{"date":80,"type":32},"2026-03-16",{"date":82,"type":21},"2028-08-28",{"name":63,"class":39},128,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100588107","phase-3-mirikizumab-administered-at-the-same-time-as-tirzepatide-in-adult-participants-with-moderately-to-severely-active-ulcerative-colitis-and-obesity-or-overweight-phase-3b-study-100588107","NCT06937086","Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study","A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight","COMMIT-UC","Inclusion Criteria:\n\n* Have had an established diagnosis of UC for ≥3 months before baseline which includes endoscopic evidence of UC and a histopathology report that supports a diagnosis of UC.\n* Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5 to 9 points and endoscopic subscore (ES) of 2 to 3 (confirmed by central review) within 21 days before baseline.\n* Participants with a history of UC for greater than or equal to 8 years who have had a surveillance colonoscopy completed within 1 year prior to baseline must have documented negative results for colorectal dysplasia and cancer.\n* Have obesity, \\[body mass index (BMI) 30 kilograms per meter squared (kg\u002Fm2)\\]\n* Have overweight (BMI ≥27 kg\u002Fm2 to \\\u003C30 kg\u002Fm2) and in the presence of at least 1 of these weight-related comorbid conditions:\n\n  * hypertension\n  * Type 2 Diabetes Mellitus (T2DM)\n  * dyslipidemia\n  * obstructive sleep apnea, or\n  * cardiovascular disease.\n* Have an inadequate response to, loss of response to, or intolerance to at least 1 of the conventional medication: oral corticosteroids, oral azathioprine (AZA) or 6-mercaptopurine (6-MP), or oral 5-aminosalicylates (for example, mesalamine, sulfasalazine, olsalazine, and balsalazide) and\u002For who have an inadequate response to or a loss of response to, or are intolerant to advanced therapy for UC, defined as: a biologic or biosimilar medication such as anti-tumor necrosis factor (TNF) antibodies; anti-integrin antibodies, Janus kinase (JAK) inhibitors such as tofacitinib or upadacitinib, sphingosine 1-phosphate receptor 1inhibitors such as etrasimod or ozanimod, or anti-interleukin(IL)-12p40 antibodies, for example, ustekinumab.\n\nExclusion Criteria:\n\n* Have a current diagnosis of:\n\n  * Crohn's disease\n  * inflammatory bowel disease (IBD) unclassified (formerly known as indeterminate colitis), or\n  * primary sclerosing cholangitis.\n* Have had or will need bowel resection or intestinal or intra-abdominal surgery.\n* Have evidence of toxic megacolon, or stricture or stenosis within the colon that cannot be traversed by a sigmoidoscope or colonoscope.\n* Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.\n* Have a history of severe hypoglycemia and\u002For hypoglycemia unawareness within the 6 months prior to screening.\n* Have a self-reported change in body weight greater than 5% (gain or reduction) within 3 months prior to screening.\n* Have a current or recent acute, active infection.","70 Years",{"count":95,"type":21},350,[24],"The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.\n\nParticipation in this study will last up to 61 weeks, including 52 weeks of treatment.",[99,27],"Ulcerative Colitis",{"date":57,"type":32},{"date":102,"type":32},"2025-06-26",{"date":104,"type":21},"2028-04",{"name":106,"class":39},"Eli Lilly and Company",189,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100588108","phase-3-mirikizumab-and-tirzepatide-administered-in-adult-participants-with-moderately-to-severely-active-crohns-disease-and-obesity-or-overweight-100588108","NCT06937099","Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","COMMIT-CD","Inclusion Criteria:\n\n* Have a confirmed diagnosis of Crohn's disease (CD) or perianal fistulizing CD\n* Have obesity body mass index 30 kilograms per meter squared (BMI ≥30 kg\u002Fm²), or overweight (BMI ≥27 kg\u002Fm2 to \\\u003C30 kg\u002Fm²) and in the presence of at least 1 weight-related comorbid conditions:\n\n  * hypertension\n  * Type 2 diabetes mellitus (T2DM)\n  * dyslipidemia\n  * obstructive sleep apnea, or\n  * cardiovascular disease.\n* Have moderately to severely active CD defined by a CDAI score of at least 220 at baseline.\n* Have a centrally read Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥6 for patients with ileal-colonic or ≥4 for patients with isolated ileal disease within 21 days before the first dose of study treatment.\n* Participants with a history of CD for ≥8 years involving only or predominantly the colon must have documented negative results for colorectal dysplasia and cancer within 1 year prior to baseline.\n* Demonstrated inadequate response, loss of response or intolerance to at least one protocol-specified conventional or advanced CD therapy\n\nExclusion Criteria:\n\n* Have a current diagnosis of Ulcerative Colitis (UC), inflammatory bowel disease-unclassified (formerly known as indeterminate colitis), or primary sclerosing cholangitis.\n* Have more than 2 missing segments of the following 5 segments: terminal ileum, ·right colon, transverse colon, ·left colon, and rectum.\n* Currently have or are suspected to have an abscess.\n* Have a stoma, ileoanal pouch, or ostomy.\n* Have a history of more than 3 small bowel resections, total resection of small bowel greater than 100 centimeters (cm), diagnosis of short bowel syndrome, or any intestinal or non-intestinal intra-abdominal surgery within 3 months of baseline.\n* Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.\n* Have a history of severe hypoglycemia and\u002For hypoglycemia unawareness within the 6 months prior to screening.\n* Have had more than 5% body weight change in the past 3 months\n* Have a current or recent acute, active infection.",{"count":117,"type":21},290,[24],"The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.\n\nThe maximum duration of this study is up to 61 weeks.",[121,27],"Crohn's Disease",{"date":57,"type":32},{"date":102,"type":32},{"date":125,"type":21},"2028-05",{"name":106,"class":39},186,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100643077","phase-2-a-dose-finding-study-of-petrelintide-with-enicepatide-ro7795068-in-adults-with-obesity-or-overweight-100643077","NCT07589686","A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight","ZYNERGY","Key Inclusion Criteria:\n\n* Male or female participants with Body Mass Index (BMI) ≥ 30 kg\u002Fm² OR BMI ≥ 27 kg\u002Fm² to \\\u003C 30 kg\u002Fm² with at least one weight-related comorbidity\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nKey Exclusion Criteria:\n\n* HbA1c ≥ 48 mmol\u002Fmol (6.5%) at screening\n* History of Type 1 or Type 2 Diabetes\n* Self-reported change in body weight \\> 5 kg within 90 days prior to screening\n* Previous or planned obesity treatment with surgery (excluding liposuction, cryolipolysis, or abdominoplasty if performed \\> 1 year prior to or during screening)\n* Previous or planned endoscopic and\u002For device-based obesity treatment or removal or device within the last 6 months prior to screening (e.g., mucosal ablation, gastric artery embolization, intragastric balloon and duodenal-jejunal endoluminal liner)\n* Treatment with any GLP-1 receptor agonist, GLP-1\u002FGIP receptor agonist (or any other GLP-1 based treatment) within 180 days prior to or during screening\n* Current or previous treatment with petrelintide or any other amylin analog\n* Obesity induced by Cushing syndrome or a diagnosis of monogenetic or syndromic forms of obesity\n* History of severe psychiatric disorders\n* History of any hematologic conditions that may interfere with HbA1c measurement\n* Known history or presence of pancreatitis\n* Known clinically significant gastric emptying abnormality or chronic treatment that affects GI motility\n* New York Heart Association Functional Classification IV heart failure\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within the time frame in which contraception is required",{"count":137,"type":21},486,[139],"PHASE2","The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.",[27],"NOT_YET_RECRUITING","2026-06-10",{"date":145,"type":32},"2026-06-12",{"date":147,"type":21},"2026-06-30",{"date":149,"type":21},"2028-01-31",{"name":63,"class":39},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100602851","phase-1-study-on-gastric-emptying-effect-and-drug-drug-interactions-of-gzr18-injection-100602851","NCT07128888","Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection","A Study to Evaluate the Effect of GZR18 Injection on Gastric Emptying and Its Drug-Drug Interactions With Digoxin, Rosuvastatin Calcium and Warfarin Sodium in Obese or Overweight Subjects","Inclusion Criteria:\n\n* 1.Obese Chinese subjects, who voluntarily sign the Informed Consent Form (ICF), can receive SC injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on contraindications and restrictions specified in this protocol.\n\n  2\\. Male or female, 18 to 50 years of age at signing the ICF (both inclusive).\n\n  3\\. Body mass index (BMI) within 26-35 kg\u002Fm2 (both ends inclusive) at screening.\n\n  4\\. No abnormality or not clinically significant abnormality as judged by the investigator in physical examination, vital signs, routine laboratory tests (hematology, blood chemistry, urinalysis, thyroid function and coagulation), 12-lead ECG, ultrasonography of liver, gallbladder, pancreas, and spleen + both kidneys, chest imaging examination and other results. (abnormal indicators related to obesity or overweight, and the investigator assesses that they have no impact on this study, they can be enrolled)\n\n  5\\. Subjects of childbearing potential with no birth plan from the signing of the ICF to 8 weeks after the last dose, willingness to take effective contraceptive measures, and no plan for sperm or ovum donation. Females of childbearing potential must not be lactating and must have negative results for blood pregnancy test at screening (including D-1).\n\nExclusion Criteria:\n\n* 1.Subjects with a previous or existing history of heart, liver, kidney, gastrointestinal tract, respiratory system, nervous system, psychiatric disorders, endocrine diseases (except obesity), malignant tumors and other diseases that are judged by the investigator to have an impact on the evaluation of the results of this study.\n\n  2\\. History or existing diseases that increase the risk of subjects, such as hypoglycemia, acute or chronic pancreatitis, pancreatic injury, history of symptomatic gallbladder disease; cholelithiasis with high risk of acute biliary pancreatitis at screening (e.g., silt-like lithiasis, gallbladder or bile duct stone ≤ 5 mm in diameter)，newly diagnosed cholecystitis at screening.\n\n  3\\. Subjects with previous or existing clinically significant digestive system diseases who are judged unsuitable for the study by the investigator, such as history of active peptic ulcer or hemorrhage, inflammatory bowel disease, abnormal gastric emptying (such as gastric paresis or pyloric stenosis, gastric outlet obstruction), continuous use of drugs affecting gastrointestinal motility for ≥ 1 week (including but not limited to domperidone, mosapride, macrolides), and acute hemorrhoidal attacks within the past three months.\n\n  4\\. History or family history of previous or existing medullary thyroid carcinoma, multiple endocrine neoplasia type 2.\n\n  5\\. Subjects who have used any drugs that alter the activity of drug metabolizing enzymes or transporters within 4 weeks prior to screening, or subjects with acute diseases or concomitant medication from the screening period to before administration of the investigational medicinal product (IMP).\n\n  6\\. Subjects with severe infection or unexplained infection within 4 weeks before screening.\n\n  7\\. Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.\n\n  8\\. Subjects with allergic constitution prior to screening, or a history of bronchial asthma, eczema and other allergic diseases (except mild seasonal allergy), or a history of severe food allergy (such as laryngeal edema, shock), or known allergy to any ingredient in investigational medicinal products (IMPs) \\[GLP-1 receptor (GLP-1R) agonist, paracetamol, digoxin, rosuvastatin, warfarin and their excipients\\].\n\n  9\\. Use of any prescription drugs, over-the-counter drugs or Chinese herbal medicines within 2 weeks prior to screening; or use of any GLP-1R agonists or drugs with the same mechanism of action to GLP-1R agonists \\[such as GLP-1R\u002Fglucagon receptor (GCGR) agonists or gastric inhibitory polypeptide receptor (GIPR)\u002FGLP-1R agonists or GIPR\u002FGLP-1R\u002FGCGR agonists\\] within 6 months prior to screening; or use of any weight loss drugs within 6 months prior to screening.\n\n  10\\. Subjects who have been vaccinated within 1 month before screening or are scheduled for vaccination during the study.","50 Years",{"count":160,"type":21},60,[162],"PHASE1","This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of GZR18 Injection on gastric emptying and the effect of repeated SC injections of GZR18 Injection on the pharmacokinetics of oral digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets.\n\nA total of 60 obese or overweight subjects are planned to be enrolled, with no less than one-quarter of the subjects from either gender.\n\nThe study duration for each subject in this study is approximately 26 weeks: including a screening period of up to 4 weeks (W-28 to D-1), single-drug administration and dose escalation stages of 16 weeks (W1D1 to W16D7) and the combined drug administration stage of 6 weeks (W17D1 to W23D1)",[27],"2025-12-10",{"date":167,"type":32},"2025-12-12",{"date":169,"type":32},"2025-11-17",{"date":171,"type":21},"2026-07-05",{"name":173,"class":39},"Gan & Lee Pharmaceuticals.",1]